Hundreds of Tylenol lawsuits are now pending in federal court on behalf of individuals who allegedly suffered liver injuries from the acetaminophen in Tylenol products.
New York, New York (PRWEB) June 10, 2014
As Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has issued yet another caution regarding the potential for acetaminophen, the active ingredient in Tylenol-brand over-the-counter products, to cause liver damage. According to a Consumer Alert posted on May 28, 2014, overdoses of acetaminophen are the most common cause of drug-related liver injury. Among other things, incidents of serious liver damage have occurred among consumers who used both an over-the-counter acetaminophen medication along with a prescription drug that also contains the ingredient. Such incidents have been responsible for a significant proportion of all the cases of acetaminophen-related liver failure in the U.S., some of which have resulted in liver transplantation and death.
“Hundreds of Tylenol lawsuits are now pending in federal court on behalf of individuals who allegedly suffered liver injuries from the acetaminophen in Tylenol products. It is important that the public understand that these types of medications can be associated with significant risks,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.
Tylenol Liver Damage Allegations
Court documents indicate that more than 140 Tylenol lawsuits are now pending in the U.S. District Court, Eastern District of Pennsylvania, all of which allege the acetaminophen in Tylenol-brand products caused consumers to sustain serious liver injuries, even when the over-the-counter medications were used in accordance with label directions. Among other things, these lawsuits allege that Johnson & Johnson and McNeil Consumer Healthcare failed to provide consumers with adequate warnings regarding the association between Tylenol and liver damage. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
In January, the FDA warned doctors not to prescribe medications that contain more than 325 milligrams of acetaminophen, due to the risk of liver damage posed by such products. In April, the FDA announced that prescription drugs containing more than 325 milligrams of acetaminophen were no longer considered safe and were being voluntarily removed from the market. The agency also reminded pharmacists to stop dispensing high-dose prescription acetaminophen products, and to return any such medications they have in stock to the wholesaler or manufacturer.*
The FDA’s new limits on prescription medications do not apply to over-the-counter acetaminophen products. In August 2013, Bloomberg.com reported that over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the new limits for prescription medications set by the FDA. That same month, Johnson & Johnson’s McNeil Consumer Healthcare unit announced that it would add new, more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medications.**
Alleged victims of acetaminophen-induced liver damage caused by a Tylenol-brand over-the-counter product may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP